NanoVibronix, Inc. (NAOV) financial statements (2021 and earlier)
Company profile
| Business Address |
525 EXECUTIVE BLVD ELMSFORD, NY 10523 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 1,338 | 896 | 4,360 | 106 | |||
| Cash and cash equivalents | 1,338 | 896 | 4,360 | 106 | |||
| Receivables | 111 | 144 | 24 | 6 | |||
| Inventory, net of allowances, customer advances and progress billings | 121 | 144 | 76 | 67 | |||
| Inventory | 121 | 144 | 76 | 67 | |||
| Prepaid expense | 249 | 42 | 45 | 34 | |||
| Other current assets | 19 | ||||||
| Other undisclosed current assets | 4 | 11 | 8 | ||||
| Total current assets: | 1,838 | 1,230 | 4,516 | 221 | |||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 4 | 8 | 6 | 11 | |||
| Prepaid expense | 5 | 5 | |||||
| Other undisclosed noncurrent assets | 194 | 346 | 338 | 257 | |||
| Total noncurrent assets: | 198 | 354 | 349 | 273 | |||
| Other undisclosed assets | (4) | ||||||
| TOTAL ASSETS: | 2,036 | 1,580 | 4,865 | 494 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 129 | 797 | 565 | ||||
| Accounts payable | 129 | 168 | 82 | ||||
| Accrued liabilities | 150 | 99 | |||||
| Employee-related liabilities | 219 | 170 | |||||
| Taxes payable | 260 | 214 | |||||
| Other undisclosed current liabilities | 280 | 640 | |||||
| Total current liabilities: | 409 | 640 | 797 | 565 | |||
| Noncurrent Liabilities | |||||||
| Liabilities, other than long-term debt | 279 | 477 | 434 | 349 | |||
| Accounts payable and accrued liabilities | 279 | 477 | 434 | 349 | |||
| Other undisclosed noncurrent liabilities | 640 | 2,079 | |||||
| Total noncurrent liabilities: | 279 | 1,117 | 434 | 2,428 | |||
| Other undisclosed liabilities | (640) | ||||||
| Total liabilities: | 688 | 1,117 | 1,231 | 2,993 | |||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent, including: | 1,348 | 463 | 3,634 | (2,499) | |||
| Common stock | 5 | 4 | 4 | 2 | |||
| Additional paid in capital | 39,669 | 32,993 | 32,010 | 20,073 | |||
| Accumulated deficit | (38,330) | (32,563) | (28,382) | (22,576) | |||
| Other undisclosed stockholders' equity attributable to parent | 4 | 29 | 2 | 2 | |||
| Total stockholders' equity: | 1,348 | 463 | 3,634 | (2,499) | |||
| TOTAL LIABILITIES AND EQUITY: | 2,036 | 1,580 | 4,865 | 494 | |||
Income statement (P&L) ($ in thousands)
| 9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | ||
|---|---|---|---|---|---|---|
| Revenues | 530 | 318 | 239 | 229 | ||
| Revenue, net | ✕ | ✕ | ✕ | 437 | ||
| Cost of revenue | (249) | (158) | (88) | (88) | ||
| Gross profit: | 281 | 160 | 151 | 141 | ||
| Operating expenses | (5,432) | (4,463) | (3,242) | (2,457) | ||
| Operating loss: | (5,151) | (4,303) | (3,091) | (2,316) | ||
| Nonoperating income (expense) | 102 | (22) | (1,836) | (398) | ||
| Investment income, nonoperating | 102 | |||||
| Other nonoperating expense | (22) | (1,836) | (398) | |||
| Interest and debt expense | (303) | (37) | ||||
| Loss from continuing operations before equity method investments, income taxes: | (5,352) | (4,325) | (4,964) | (2,714) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | (459) | 44 | 37 | |||
| Loss from continuing operations before income taxes: | (5,811) | (4,281) | (4,927) | (2,714) | ||
| Income tax expense (benefit) | 17 | 127 | (38) | (117) | ||
| Net loss attributable to parent: | (5,794) | (4,154) | (4,965) | (2,831) | ||
| Preferred stock dividends and other adjustments | (841) | |||||
| Net loss available to common stockholders, diluted: | (5,794) | (4,154) | (5,806) | (2,831) | ||
Comprehensive Income ($ in thousands)
| 9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | ||
|---|---|---|---|---|---|---|
| Net loss: | (5,794) | (4,154) | (4,965) | (2,831) | ||
| Comprehensive loss: | (5,794) | (4,154) | (4,965) | (2,831) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (841) | |||||
| Comprehensive loss, net of tax, attributable to parent: | (5,794) | (4,154) | (5,806) | (2,831) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.